The report will be delivered in 2-3 business days.

Rituximab Biosimilars Global Market Report 2020-30: Covid 19 Growth and Change

Starting Price : $ 4000.00 | Pages : 150 | Published : September 2020 | SKU CODE : | Format :


The rituximab biosimilars market consists of sales of rituximab biosimilars. Biosimilars are pharmaceuticals that are manufactured using cell lines and are similar to biologics. Rituximab biosimilars are used as a single agent or in combination with chemotherapy for the treatment of various diseases including chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), microscopic polyangiitis (MPA), and granulomatosis with polyangiitis (GPA).

The global rituximab biosimilars market is expected to decline from $1.84 billion in 2019 to $1.78 billion in 2020 at a compound annual growth rate (CAGR) of -3.22%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $2.62 billion in 2023 at a CAGR of 13.85%.

The rising prevalence of non-Hodgkin`s lymphoma (NHL) is predicted to contribute to the growth of the rituximab biosimilars market. Non-Hodgkin`s lymphoma or lymphoma is cancer that starts in white blood cells (lymphocytes) that are part of the body’s immune system. In 2018, rituximab-abbs was approved as the first rituximab biosimilars for the treatment of patients with B-cell non-Hodgkin lymphoma (NHL) and adult patients with CD20-positive. According to the National Library of Medicine’s statistics, non-Hodgkin lymphoma (NHL) was ranked as 5th to 9th most common cancers in most of the countries, with approximately 5,10,000 new cases in 2018, globally. Moreover, according to the American Cancer Society, NHL is the most common cancer in the USA. About 77,240 people (34,860 females and 42,380 males) are estimated to be diagnosed with NHL by the end of 2020 in the USA. Thus, growing cases of non-Hodgkin`s lymphoma are predicted to generate high demand for rituximab biosimilars over the forecast period.

The high cost associated with rituximab biosimilars acts as a major restraint for the growth of rituximab’s market over the coming years. The cost of the subcutaneous option was costlier than IV biosimilar rituximab. The cost of subcutaneous formulation for patients with small body size is between $3,805 and $8,807 and for medium body size between $325 to $6,109 and $484 to $6,267 for 2 infusion speeds. The high costs of rituximab biosimilars make it unaffordable for the treatment of patients with low income, hindering the growth of the market.

The companies operating in the biosimilars market are continuously focusing on new product development in collaborations with other companies in the industry. Innovation through partnerships is shaping the rituximab biosimilars market. For instance, in May 2020, Teva Pharmaceutical Industries Ltd. and Celltrion Healthcare Co. Ltd together announced the launch of biosimilar Truxima (rituximab-abbs) injection in the USA for the treatment of polyangiitis and rheumatoid arthritis. Truxima is the only biosimilar to Roche`s Rituxan (rituximab) available in the USA for the treatment of rheumatoid arthritis.

Europe was the largest region in the rituximab biosimilars market in 2019. Asia-Pacific is expected to be the fastest-growing region in the forecast period.

The major players covered in the global rituximab biosimilars market are Pfizer Inc., Mylan Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co. Ltd., Sandoz International GmbH, Reliance Life Sciences, C.H. Boehringer Sohn AG & Ko. KG, BioXpress Therapeutics SA, Intas Biopharmaceuticals Ltd.

The countries covered in the global rituximab biosimilars market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The regions covered in the global rituximab biosimilars market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The global rituximab biosimilars market is segmented - 1) By Application: Non-Hodgkin’s lymphoma, Chronic Lymphocytic Leukemia, Rheumatoid arthritis, Others 2) Hospital Pharmacy: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Direct Distribution Channels.

    1. Executive Summary

    2. Rituximab Biosimilars Market Characteristics

    3. Rituximab Biosimilars Market Size And Growth

    3.1. Global Rituximab Biosimilars Historic Market, 2015 - 2019, $ Billion

    3.1.1. Drivers Of The Market

    3.1.2. Restraints On The Market

    3.2. Global Rituximab Biosimilars Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion

    3.2.1. Drivers Of The Market

    3.2.2. Restraints On the Market

    4. Rituximab Biosimilars Market Segmentation

    4.1. Global Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    Non-Hodgkin’s lymphoma

    Chronic Lymphocytic Leukemia

    Rheumatoid arthritis

    Others

    4.2. Global Rituximab Biosimilars Market, Segmentation Hospital Pharmacy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    Hospital Pharmacy

    Online Pharmacy

    Retail Pharmacy

    Other Direct Distribution Channels

    5. Rituximab Biosimilars Market Regional And Country Analysis

    5.1. Global Rituximab Biosimilars Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    5.2. Global Rituximab Biosimilars Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    6. Asia-Pacific Rituximab Biosimilars Market

    6.1. Asia-Pacific Rituximab Biosimilars Market Overview

    6.2. Asia-Pacific Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    7. China Rituximab Biosimilars Market

    7.1. China Rituximab Biosimilars Market Overview

    7.2. China Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

    8. India Rituximab Biosimilars Market

    8.1. India Rituximab Biosimilars Market Overview

    8.2. India Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    9. Japan Rituximab Biosimilars Market

    9.1. Japan Rituximab Biosimilars Market Overview

    9.2. Japan Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    10. Australia Rituximab Biosimilars Market

    10.1. Australia Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    11. Indonesia Rituximab Biosimilars Market

    11.1. Indonesia Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    12. South Korea Rituximab Biosimilars Market

    12.1. South Korea Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    13. Western Europe Rituximab Biosimilars Market

    13.1. Western Europe Rituximab Biosimilars Market Overview

    13.2. Western Europe Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    14. UK Rituximab Biosimilars Market

    14.1. UK Rituximab Biosimilars Market Overview

    14.2. UK Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    15. Germany Rituximab Biosimilars Market

    15.1. Germany Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    16. France Rituximab Biosimilars Market

    16.3. France Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    17. Eastern Europe Rituximab Biosimilars Market

    17.1. Eastern Europe Rituximab Biosimilars Market Overview

    17.2. Eastern Europe Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    18. Russia Rituximab Biosimilars Market

    18.1. Russia Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    19. North America Rituximab Biosimilars Market

    19.1. North America Rituximab Biosimilars Market Overview

    19.2. North America Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    20. USA Rituximab Biosimilars Market

    20.1. USA Rituximab Biosimilars Market Overview

    20.2. USA Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    21. South America Rituximab Biosimilars Market

    21.1. South America Rituximab Biosimilars Market Overview

    21.2. South America Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    22. Brazil Rituximab Biosimilars Market

    22.1. Brazil Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    23. Middle East Rituximab Biosimilars Market

    23.1. Middle East Rituximab Biosimilars Market Overview

    23.2. Middle East Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    24. Africa Rituximab Biosimilars Market

    24.1. Africa Rituximab Biosimilars Market Overview

    24.2. Africa Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    25. Rituximab Biosimilars Market Competitive Landscape And Company Profiles

    25.1. Rituximab Biosimilars Market Competitive Landscape

    25.2. Rituximab Biosimilars Market Company Profiles

    25.2.1. Pfizer Inc.

    25.2.1.1. Overview

    25.2.1.2. Products and Services

    25.2.1.3. Strategy

    25.2.1.4. Financial Performance

    25.2.2. Mylan Inc.

    25.2.2.1. Overview

    25.2.2.2. Products and Services

    25.2.2.3. Strategy

    25.2.2.4. Financial Performance

    25.2.3. Amgen Inc.

    25.2.3.1. Overview

    25.2.3.2. Products and Services

    25.2.3.3. Strategy

    25.2.3.4. Financial Performance

    25.2.4. Teva Pharmaceutical Industries Ltd.

    25.2.4.1. Overview

    25.2.4.2. Products and Services

    25.2.4.3. Strategy

    25.2.4.4. Financial Performance

    25.2.5. Celltrion Healthcare Co.,Ltd.

    25.2.5.1. Overview

    25.2.5.2. Products and Services

    25.2.5.3. Strategy

    25.2.5.4. Financial Performance

    26. Key Mergers And Acquisitions In The Rituximab Biosimilars Market

    27. Rituximab Biosimilars Market Trends And Strategies

    28. Rituximab Biosimilars Market Future Outlook and Potential Analysis

    29. Appendix

    29.1. Abbreviations

    29.2. Currencies

    29.3. Research Inquiries

    29.4. The Business Research Company

    29.5. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2015-2019, $ Billion
  • Table 2: Global Forecast Market Growth, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 3: Global Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 4: Global Rituximab Biosimilars Market, Segmentation Hospital Pharmacy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 5: Global Rituximab Biosimilars Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 6: Global Rituximab Biosimilars Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 7: Asia-Pacific, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 8: China, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 9: India, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 10: Japan, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 11: Australia, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 12: Indonesia, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 13: South Korea, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 14: Western Europe, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 15: UK, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 16: Germany, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 17: France, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 18: Eastern Europe, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 19: Russia, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 20: North America, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 21: USA, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 22: South America, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 23: Brazil, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 24: Middle East, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 25: Africa, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 26: Pfizer Inc. Financial Performance
  • Table 27: Mylan Inc. Financial Performance
  • Table 28: Amgen Inc. Financial Performance
  • Table 29: Teva Pharmaceutical Industries Ltd. Financial Performance
  • Table 30: Celltrion Healthcare Co.,Ltd. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2015-2019, $ Billion
  • Figure 2: Global Forecast Market Growth, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 3: Global Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 4: Global Rituximab Biosimilars Market, Segmentation Hospital Pharmacy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 5: Global Rituximab Biosimilars Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 6: Global Rituximab Biosimilars Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 7: Asia-Pacific, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 8: China, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 9: India, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 10: Japan, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 11: Australia, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 12: Indonesia, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 13: South Korea, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 14: Western Europe, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 15: UK, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 16: Germany, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 17: France, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 18: Eastern Europe, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 19: Russia, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 20: North America, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 21: USA, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 22: South America, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 23: Brazil, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 24: Middle East, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 25: Africa, Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 26: Pfizer Inc. Financial Performance
  • Figure 27: Mylan Inc. Financial Performance
  • Figure 28: Amgen Inc. Financial Performance
  • Figure 29: Teva Pharmaceutical Industries Ltd. Financial Performance
  • Figure 30: Celltrion Healthcare Co.,Ltd. Financial Performance
New Drug Innovations In The Pharmaceuticals Market
Antithrombotic Drugs Are Being Used To Prevent Various Disorders
Increasing Rate Of The Elder Population Is Driving The Ophthalmology Drugs Market
Innovations In The Diabetes Therapies Market
Allergan plc- One Of The Largest Companies In The Global Drugs For Benign Prostatic Hypertrophy Market
Innovation And Development Of Combination Drugs To Enhance Growth Of The Ovarian Cancer Drugs Market
The Global Prostate Cancer Drugs Market Will Reach Around $10 By 2022
Antivirals Are The Largest And Fastest Growing Segment Of The Anti-Infective Drugs Market
Oncology Drugs Market - By Type (Blood Cancer, Breast Cancer, Lung Cancer, Prostate cancer, Colorectal Cancer, Cervical cancer, Kidney cancer, Gastric Cancer, Brain Tumor, Skin Cancer, Ovarian Cancer, Bladder Cancer, Pancreatic Cancer, Thyroid cancer, Others), By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy, Hormonal Therapy), By Distribution Channel (Retail Pharmacies/Drug Stores, Hospital Pharmacies, Others), By Route Of Administration (Oral, Parenteral, Others), By Drug Classification (Branded, Generic), And By Region, Opportunities And Strategies - Global Forecast To 2030
View Report
Ophthalmology Drugs Market - By Type (Antglaucoma Drugs, Dry Eye Medication And Other Ophthalmological Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores And Others), By Drug Classification (Branded Drugs And Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) And, By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Dry Eye Medication Market - By Type (Aqueous Dry Eye Syndrome, Evaporative Dry Eye Syndrome), By End-User (Hospital Pharmacies, Eye Health Clinics, Retail Pharmacies, Online Pharmacies), By Product Type (Liquid Drops, Gel, Liquid Wipes, Eye Ointment), And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Coronavirus (COVID-19) Current Therapy Market Global Report 2020: COVID 19 Growth And Change
View Report
COVID19 Drug Associated APIs Market Global Report 2020: COVID 19 Growth And Change
View Report
COVID19 Vaccine & Therapeutics Clinical Trial Analysis 2020
View Report
COVID19 Vaccine And Therapeutics Pipeline Analysis 2020
View Report
Remdesivir Market Global Report 2020-30: COVID 19 Growth and Change
View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)